| Biomarker ID | 422 |
| PMID | 19229851 |
| Year | 2009 |
| Biomarker | Endoglin |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Increased Expression with Biochemical Recurrence |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR: 1.05 |
| Effect on Pathways | Pathways Include:-ALK1 pathway,HIF-1 transcriptional activity in hypoxia, TGF-beta signaling pathway |
| Experiment | Recurrence Vs No recurrence for 5 years |
| Type of Biomarker | Prognostic |
| Cohort | A cohort of 423 men was used to develop and internally validate the post-operative nomogram for prediction of Biochemical Recurrance. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | Concordance Index = 86.2% |
| Level Of Significance | p<0.001 |
| Method Used | enzyme immunoassays |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | ENG |